Ranbezolid

Ranbezolid is an oxazolidinone antibiotic that is currently under development. It is a synthetic antibacterial agent that has demonstrated significant in vitro and in vivo activity against a broad spectrum of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

Mechanism of Action[edit | edit source]

Ranbezolid inhibits protein synthesis in bacteria by binding to the ribosome and blocking the formation of a functional 70S-initiation complex. This is a critical step in the bacterial translation process and is therefore a point of attack for several antibiotic classes.

Pharmacokinetics[edit | edit source]

Ranbezolid is well absorbed after oral administration and has a bioavailability of approximately 90%. It is extensively distributed to tissues and fluids, including lung tissue and cerebrospinal fluid. The drug is primarily metabolized by the liver and excreted in the urine and feces.

Clinical Trials[edit | edit source]

Ranbezolid has undergone Phase 2 clinical trials for the treatment of complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria, including MRSA and VRE. The results of these trials have shown that ranbezolid is well tolerated and effective in the treatment of these infections.

Side Effects[edit | edit source]

The most common side effects of ranbezolid include nausea, vomiting, diarrhea, and headache. Less common side effects include dizziness, insomnia, and rash.

See Also[edit | edit source]

Ranbezolid Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.